Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-04-19
1996-08-20
Springer, David B.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
548550, 548551, A61K 3140
Patent
active
055479790
ABSTRACT:
Derivatives of 2-pyrrolidinones are described which inhibit the production of TNF and are useful in the treatment of disease states mediated or exacerbated by TNF production.
REFERENCES:
patent: 3923833 (1975-12-01), Gruenman et al.
patent: 4012495 (1977-03-01), Schmiechen et al.
patent: 4034087 (1977-07-01), Voorhees
patent: 4153713 (1979-05-01), Huth et al.
patent: 4186129 (1980-01-01), Huth et al.
patent: 4193926 (1980-03-01), Schmiechen et al.
Lee et al., Int. J. Immunotherapy, VI (1) pp. 1 to 12 (1990).
Peachell et al., FASEB J., vol. 4, p. A639, Abstract #2163 (1990).
Internat'l Conference, 5th Dec. 1988, Royal Lancaster Hotel, London, "Xanthines".
Frohlich et al., Abstract, J. Invest. Dermatology 90: 240 (1988).
Marivet et al., J. Med. Chem., 32, pp. 1450-1457 (1989).
Torphy, New Drugs for Asthma, P. J. Barnes, Ed., IBC Technical Services, Ltd., London 1989, Chapter 7, pp. 66-77.
Renz et al., J. Immunol., Release of Tumor Necrosis Factor-.alpha.From Macrophages, vol. 141(7), 2388-2393 (1988).
Christensen, IV Siegfried B.
Esser Klaus M.
Simon Philip L.
Dinner Dara L.
Lentz Edward T.
SmithKline Beecham
Springer David B.
Venetianer Stephen
LandOfFree
TNF inhibition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with TNF inhibition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TNF inhibition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2331047